First Amendment Suit: FDA Draws Line At Amarin's Heart Disease Claim
This article was originally published in The Tan Sheet
Amarin Pharmaceuticals’ marketing plan for its Rx fish oil drug Vascepa, including noting the qualified heart health claim allowed for omega-3 supplements, could “establish precedent that would return the country to ... when companies were not required to prove that their drugs were safe and effective for each of their intended uses,” FDA argues.
You may also be interested in...
Ongoing cases led by New York's Preet Bharara and other US attorneys are unlikely to be affected though their successors could focus on different areas; Boston US Attorney Carmen Ortiz resigned in December.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.